金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01548 金斯瑞生物科技

已收盘 04-30 16:08:13

13.720

+0.100

+0.73%

最高13.840	最低13.370	成交量692.52万
今开13.450	昨收13.620	日振幅3.45%
总市值300.19亿	流通市值300.19亿	总股本21.88亿
成交额9,479万	换手率0.32%	流通股本21.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01548","market":"HK","secType":"STK","nameCN":"金斯瑞生物科技","latestPrice":13.72,"timestamp":1777536493003,"preClose":13.62,"halted":0,"volume":6925185,"delay":0,"changeRate":0.007342143906020663,"floatShares":2188000000,"shares":2188000000,"eps":-1.9256079217849082,"marketStatus":"已收盘","change":0.1,"latestTime":"04-30 16:08:13","open":13.45,"high":13.84,"low":13.37,"amount":94793183,"amplitude":0.034508,"askPrice":13.73,"askSize":66000,"bidPrice":13.72,"bidSize":56000,"shortable":3,"etf":0,"ttmEps":-1.9256079217849082,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777858200000},"marketStatusCode":5,"adr":0,"listingDate":1451404800000,"exchange":"SEHK","adjPreClose":13.62,"openAndCloseTimeList":[[1777512600000,1777521600000],[1777525200000,1777536000000]],"volumeRatio":1.068105,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01548","defaultTab":"news","newsList":[{"id":"2629703503","title":"港股异动 | 金斯瑞生物科技(01548)早盘涨超8% 礼来70亿美元天价收购in vivo CAR-T公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2629703503","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629703503?lang=zh_cn&edition=full","pubTime":"2026-04-21 09:37","pubTimestamp":1776735476,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技早盘涨超8%，截至发稿，涨6.84%，报14.68港元，成交额1.07亿港元。消息面上，礼来正式宣布以32.5亿美元首付款、最高70亿美元的总对价，收购波士顿生物技术公司Kelonia。据悉，Kelonia的核心技术为iGPS，是一种基于改造过的慢病毒载体的in vivo（体内）CAR-T平台。国泰海通证券指出，in vivo CAR-T兼具制造简化、可及性提升与平台延展性强等优势，持续看好其成为下一代细胞治疗重要方向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"港股异动 | 金斯瑞生物科技(01548)早盘涨超8% 礼来70亿美元天价收购in vivo CAR-T公司","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1551013342.USD","LLII","LU0106261372.USD","LU2756315318.SGD","SG9999018857.SGD","HK0000320264.USD","LU0203201768.USD","LU2111349929.HKD","LU0225283273.USD","LU1720051108.HKD","LU1023059063.AUD","LU0708995401.HKD","LU2750360997.AUD","LU2746668461.USD","BK4534","IE00BK4W5M84.HKD","LU1868836757.USD","LU2746668974.SGD","LU0353189763.USD","LU2357305700.SGD","LU2028103732.USD","LU2471134879.HKD","LU2468319806.SGD","LU2237443549.SGD","ELIS","LU0354030511.USD","LU0820562030.AUD","LU2237443382.USD","LU2324357040.USD","LU1291159041.SGD","LU2750360641.GBP","SGXZ51526630.SGD","LU2112291526.USD","SG9999014880.SGD","BK4588","LU0323591593.USD","LU0882574055.USD","LU2211815571.USD","LU1145028129.USD","IE0002141913.USD","SG9999013999.USD","LU0238689110.USD","LU2237443895.HKD","SG9999015952.SGD","LU0097036916.USD","IE00BK4W5L77.USD","IE00BWXC8680.SGD","LU1548497426.USD","LU0158827781.USD","IE00BFSS7M15.SGD","LU1323610961.USD","LU2491049909.HKD","LU0094547139.USD","LU2265009873.SGD","LU2602419157.SGD","LU0122379950.USD","LU0672654240.SGD","BK4516","LU1127390331.HKD","BK4599","LU0640476718.USD","SGXZ31699556.SGD","ELIL","SGXZ99366536.SGD","LU0432979614.USD","LU0354030438.USD","LU1551013425.SGD","LU1712237335.SGD","LU0823434583.USD","LU1280957306.USD","BK1583","LU0471298777.SGD","LU0823416689.USD","GB00BDT5M118.USD","IE00B1BXHZ80.USD","IE00BJLML261.HKD","LU0882574139.USD","LU0320765059.SGD","LU0787776722.HKD","SG9999001176.SGD","BK4581","LU2106854487.HKD","LU1366192091.USD","LU2237443622.USD","LU2491050071.SGD","BK4022","LU2756315664.SGD","IE00BKDWB100.SGD","LU0198837287.USD","LU2089283258.USD","LU0133085943.USD","LU2237443978.SGD","LU2237443465.HKD","BK4007","LU0786609619.USD","LU0158827948.USD","IE00BN29S564.USD","LU0203202063.USD","SG9999014906.USD","IE00B775H168.HKD","LU2456880835.USD","LU1804176565.USD","LU1988902786.USD","LU2168564149.EUR","LU0109391861.USD","LU2361044865.SGD","HK0000306701.USD","SG9999018865.SGD","BK4585","LLYZ","LU2361044949.HKD","LU2213496289.HKD","LU2471134796.USD","LU0943347566.SGD","LU1974910355.USD","SG9999015978.USD","LU0079474960.USD","LU0058720904.USD","LU1069344957.HKD","LU0256863811.USD","LU1064131342.USD","IE0004445239.USD","SG9999001176.USD","LU0456855351.SGD","LU2023250330.USD","LU1093756325.SGD","LU0689472784.USD","LU0683600562.USD","LU1623119135.USD","LU1868836591.USD","IE00BKPKM429.USD","IE0001KFT4U8.USD","LU0471298694.HKD","LU1232071149.USD","LU2264538146.SGD","LU2108987350.USD","LU1035775433.USD","HK0000306685.HKD","LU0889565916.HKD","LU0234572021.USD","LU2471134523.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU2237438978.USD","LU0096364046.USD","LU0210536198.USD","LU2462157665.USD","LU2417539215.USD","LU0353189680.USD","LU0061475181.USD","LU2023251221.USD","LU2089284900.SGD","LU2089984988.USD","LU0289739699.SGD","LU0466842654.USD","IE0009355771.USD","LU2360106947.USD","SG9999014914.USD","LU2063271972.USD","LU2896262040.SGD","SG9999017495.SGD","LU1917777945.USD","LU0385154629.USD","SG9999015945.SGD","BK1576","SG9999014898.SGD","IE00B4JS1V06.HKD","LU1720051017.SGD","LU2491050154.USD","LU2552382215.SGD","LU0417517546.SGD","IE00BFSS8Q28.SGD","SGXZ81514606.USD","LU2361045086.USD","LU2087625088.SGD","LU2168563687.JPY","LU1093756168.USD","LU0964807845.USD","LU1983299246.USD","LU1868837136.USD","LU1989771016.USD","LU2271345857.HKD","LU0256863902.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE0004445015.USD","LLYX","LU2168564495.EUR","LU2552382058.USD","LU0109394709.USD","LU1057294990.SGD","IE00BJJMRX11.SGD","IE00B2B36J28.USD","LU2461242641.AUD","LU1629891620.HKD","LU0266013472.USD","BK4533","IE00BJJMRY28.SGD","LU2168564065.EUR","LU2552382132.HKD","LU1814569148.SGD","LU1868836914.USD","BK4230","LU2471134952.CNY","LU0114720955.EUR","LU0320765992.SGD","LU0316494557.USD","LU0820561818.USD","LU0823434740.USD","LU1267930730.SGD","01548","HK0000320223.HKD","LU0006306889.USD","IE0005OL40V9.USD","LU2023250504.SGD","LU0820561909.HKD","IE00B1XK9C88.USD","SG9999015986.USD","BK1141","LU1868837300.USD","LU2236285917.USD","IE00B7KXQ091.USD","SGXZ57979304.SGD","LU1061106388.HKD","LU2168564222.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627403343","title":"港股金斯瑞生物科技一度涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627403343","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627403343?lang=zh_cn&edition=full","pubTime":"2026-04-15 13:46","pubTimestamp":1776232015,"startTime":"0","endTime":"0","summary":"4月15日，金斯瑞生物科技(01548.HK)午后一度涨超4%，截至发稿涨3.78%，报13.18港元，成交额9341.81万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705770352.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705770352.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","HK0000320223.HKD","BK1576","HK0000306701.USD","VXUS","BK1583","BK1141","HK0000306685.HKD","BK4588","01548","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627445675","title":"金斯瑞生物科技(01548)：CARVYKTI®于截至2026年3月31日止季度产生贸易销售净额约5.97亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627445675","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627445675?lang=zh_cn&edition=full","pubTime":"2026-04-14 20:00","pubTimestamp":1776168032,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技(01548)发布公告，根据传奇生物科技股份有限公司(为公司联营公司，其股份以美国存托股份形式于美国纳斯达克全球精选市场上市)与Janssen Biotech, Inc.(杨森)于2017年12月21日订立的合作及许可协议，CARVYKTI®于截至2026年3月31日止季度产生贸易销售净额约5.97亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"金斯瑞生物科技(01548)：CARVYKTI®于截至2026年3月31日止季度产生贸易销售净额约5.97亿美元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","HK0000320264.USD","01548","HK0000320223.HKD","BK1576","HK0000306701.USD","BK1141","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147061101","title":"金斯瑞生物科技授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1147061101","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147061101?lang=zh_cn&edition=full","pubTime":"2026-04-13 18:18","pubTimestamp":1776075538,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技于香港联交所主板上市，将于2026年6月5日召开股东周年大会，审议并授权董事在指定期间内回购最多相当于公司已发行股本10%的股份。截至最后实际可行日期，公司已发行股份约21.88亿股，若全部行使，该购回规模可达约2.19亿股。董事会认为本次购回安排对公司及广大股东整体利益具积极意义。根据公告，本公司拟自2026年6月2日至6月5日暂停办理股份过户，以确定具备出席股东周年大会并行使表决权的资格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627367654","title":"金斯瑞生物科技：2025年净亏损5.32亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627367654","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627367654?lang=zh_cn&edition=full","pubTime":"2026-04-13 17:17","pubTimestamp":1776071820,"startTime":"0","endTime":"0","summary":"南财智讯4月13日电，金斯瑞生物科技（01548.HK）公告，截至2025年12月31日止年度，公司持续经营业务总收益为9.60亿美元，同比增长61.4%；年内净亏损为5.32亿美元；每股基本亏损为0.25美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604133702948420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01548","BK1576","BK1583","HK0000306685.HKD","BK1141","HK0000306701.USD","HK0000320223.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125843303","title":"金斯瑞生物科技（01548）收入大幅攀升六成 多平台驱动业绩结构加速演进","url":"https://stock-news.laohu8.com/highlight/detail?id=1125843303","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125843303?lang=zh_cn&edition=full","pubTime":"2026-04-13 17:15","pubTimestamp":1776071707,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技于2025年度展现持续经营业务的高增长态势，收入较上一年大幅跃升至9.60亿美元，同比增幅达61.4%。在毛利率从45.8%提升至57.5%等多重因素推动下，公司经调整净利润达到2.30亿美元，较上年度增长285.0%。同期，集团持续经营业务录得5.32亿美元净亏损，主要源于对传奇集团的投资减值及相关投资亏损所致。整体而言，在2025年收入强劲增长的背景下，金斯瑞生物科技的业务结构和研发投入进一步优化，生物制剂CRDMO与生命科学服务的结合度不断提升。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122667081","title":"金斯瑞生物科技3月股份变动月报表更新，发行股本略有增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1122667081","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122667081?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:32","pubTimestamp":1775118751,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技股份有限公司于2026年4月2日发布截至2026年3月31日的月度股份变动报告。报告显示，公司法定股本维持在5,000,000,000股，对应注册股本5,000,000美元，较上月底无变化。本月新增股份主要包括因行使股份期权增加217,000股，以及根据股份奖励计划发行1,310,823股。公司报告期内并无购回或注销股份，亦无库藏股增加或减少。截至3月末，公司确认满足香港联交所要求的最低公众持股量。截至本次报告发布，已发行股份总数为2,188,046,343股。公告由公司董事孟建革签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623379186","title":"CXO概念股强势 凯莱英(06821)涨13.85% 机构认为CXO基本面拐点已经出现","url":"https://stock-news.laohu8.com/highlight/detail?id=2623379186","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623379186?lang=zh_cn&edition=full","pubTime":"2026-03-31 10:23","pubTimestamp":1774923794,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO概念股强势，凯莱英(06821)涨13.85%，昭衍新药(06127)涨7.34%，药明生物(02269)涨5.99%，康龙化成(03759)涨4.54%，药明康德(02359)涨4.12%，泰格医药(03347)涨2.89%，金斯瑞生物科技(01548)涨1.09%。浙商医药团队分析指出，在CXO产业持续出清，股价相对低位背景下，看好本土头部CDMO企业和受益国内需求复苏CRO企业底部投资机会。从财务、需求和供给数据分析，该机构认为CXO基本面拐点已经出现，并有望持续复苏。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977810","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","LU1242518857.USD","LU0348825331.USD","LU0417516738.SGD","LU0051755006.USD","LU0307460666.USD","06127","IE00B0JY6N72.USD","LU0181495838.USD","BK1589","LU1046422090.SGD","LU0456827905.SGD","06821","LU0516423091.SGD","LU0516422366.SGD","HK0000306701.USD","LU0856984785.SGD","LU0359201612.USD","BK1576","LU1328615791.USD","LU2045819591.USD","LU0819121731.USD","02269","01548","LU0979878070.USD","LU0327786744.USD","LU0572944931.SGD","LU0516422440.USD","LU0320764599.SGD","LU1794554557.SGD","LU1880383366.USD","LU3063872942.SGD","HK0000306685.HKD","002821","LU0823426308.USD","03347","CXO","LU0456846285.SGD","LU0516423174.USD","03759","LU0348735423.USD","LU0052750758.USD","LU0823426480.USD","02359","LU0043850808.USD","LU1688375341.USD","LU0140636845.USD","BK1521","LU0039217434.USD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620173236","title":"金斯瑞(01548)2025年报观：三大业务协同增长，体系化竞争彰显长期价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2620173236","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620173236?lang=zh_cn&edition=full","pubTime":"2026-03-18 17:00","pubTimestamp":1773824401,"startTime":"0","endTime":"0","summary":"3月15日，金斯瑞公布了2025年全年业绩。财报显示，2025年，公司持续经营业务实现收益约9.6亿美元，同比大幅增长61.4%。百斯杰的核心业务稳中有进，为中长期增长蓄力。年内，该公司持续推进多平台协同发展，积极开拓新增长曲线，形成了“基因至蛋白一体化平台”，以体系化竞争优势持续领跑。2025年，百斯杰收入约为5800万美元，同比增长7.9%;经调整毛利约为2300万美元，增速超越行业平均增速5%，迎来关键增长拐点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415428.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","01548","HK0000320223.HKD","HK0000320264.USD","BK1583","HK0000306685.HKD","BK1141","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620825832","title":"大和：降金斯瑞生物科技(01548)目标价至21港元 续予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2620825832","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620825832?lang=zh_cn&edition=full","pubTime":"2026-03-18 14:00","pubTimestamp":1773813650,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大和发布研报称，金斯瑞生物科技去年业绩符合预期，销售额同比增61%至9.6亿美元，符合该行预测的9.61亿美元;经调整净利润升285%至2.3亿美元。该行维持金斯瑞生物科技“买入”评级，目标价由26港元下调至21港元，以反映对其联营公司传奇生物的较低估值。至于今年指引，金斯瑞生物科技料Genscript Life Science收入同比增长15至18%，经调整毛行率约为52%; 经调整经营溢利约19%。另外，该行下调公司2026至27年的每股盈测10%及1%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177805767","title":"异动解读 | 年度收益大增61.4%且联营公司亏损收窄，金斯瑞生物科技盘中大涨6.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177805767","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177805767?lang=zh_cn&edition=full","pubTime":"2026-03-17 11:25","pubTimestamp":1773717902,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技今日盘中大涨6.32%，引起了市场的广泛关注。消息面上，公司发布了截至2025年12月31日止的年度业绩报告，期内取得收益9.6亿美元，同比大幅增加61.4%，主要归因于许可收益的大幅增长以及其他业务的稳健表现。收益的强劲增长带动公司毛利显著上升，持续经营业务的毛利约为5.53亿美元，较上期增长103.3%。同时，传奇生物的亏损大幅收窄至0.33亿美元，并有望在2026年实现盈利。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620412370","title":"港股异动 | 金斯瑞生物科技(01548)涨超5% 年度收益同比增加61.4% 传奇生物亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2620412370","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620412370?lang=zh_cn&edition=full","pubTime":"2026-03-17 11:15","pubTimestamp":1773717332,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技涨超5%，截至发稿，涨3.24%，报66.95港元，成交额6281.35万港元。消息面上，3月15日，金斯瑞生物科技发布截至2025年12月31日止年度业绩，该集团期内取得收益9.6亿美元，同比增加61.4%；母公司拥有人应占亏损5.33亿美元，同比盈转亏；每股基本亏损24.58美分。华泰证券指出，金斯瑞生物科技2025年业绩符合预期，各主要业务板块展现稳健增长或扭亏态势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LEGN","01548","BK4585","HK0000306701.USD","BK4139","BK4505","HK0000306685.HKD","BK1583","VXUS","HK0000320223.HKD","BK4588","BK1141","HK0000320264.USD","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167834481","title":"金斯瑞生物科技公布强劲2025财年业绩：一体化平台战略与全球化执行驱动高质量增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1167834481","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167834481?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:15","pubTimestamp":1773656134,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技公司公布了其2025财年的强劲业绩。报告显示，公司通过其一体化平台战略和高效的全球化执行能力，成功驱动了高质量的业务增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","HK0000306685.HKD","HK0000306701.USD","BK1583","HK0000320264.USD","HK0000320223.HKD","01548","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619106931","title":"金斯瑞生物科技(01548)：林慧怡已获委任为公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2619106931","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619106931?lang=zh_cn&edition=full","pubTime":"2026-03-15 19:31","pubTimestamp":1773574297,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技(01548)发布公告，黄慧玲女士(黄女士)已辞任本公司公司秘书及根据香港法例第 622章《公司条例》第16部项下的本公司授权代表 (公司条例项下的授权代表)，自 2026年3月15日起生效。林慧怡女士(林女士)已获委任为公司秘书及公司条例项下的授权代表，自2026年3月15日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","HK0000306685.HKD","01548","HK0000320223.HKD","BK1583","HK0000320264.USD","BK1576","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619106876","title":"金斯瑞生物科技：2025年净亏损5.32亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2619106876","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619106876?lang=zh_cn&edition=full","pubTime":"2026-03-15 19:14","pubTimestamp":1773573242,"startTime":"0","endTime":"0","summary":"南财智讯3月15日电，金斯瑞生物科技（01548.HK）公告，截至2025年12月31日止年度，公司总收益为9.60亿美元，同比增长61.4%；年内亏损为5.32亿美元；每股基本亏损为0.25美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603153672410538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1576","HK0000306685.HKD","HK0000306701.USD","BK1583","HK0000320264.USD","HK0000320223.HKD","01548","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145014066","title":"金斯瑞生物科技（01548）2025年股本变动：行使股份期权与限制性股份单位，股本增至2,185千美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145014066","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145014066?lang=zh_cn&edition=full","pubTime":"2026-03-15 19:11","pubTimestamp":1773573091,"startTime":"0","endTime":"0","summary":"于2024年及2025年12月31日，金斯瑞生物科技（01548）的授权股本金额均为5,000千美元。2025年1月1日，公司已发行股份数目为2,142,296,633股，对应股本2,142千美元。报告期内，因行使股份期权及限制性股份单位，新增42,408,537股，股本相应增至2,185千美元。至2025年12月31日，公司已发行股份总数增至2,184,705,170股，未见其他回购记录或关于其他激励计划的信息。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618718200","title":"【新股IPO】据报传奇生物计划今年在香港上市 集资3亿至4亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618718200","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618718200?lang=zh_cn&edition=full","pubTime":"2026-03-12 17:07","pubTimestamp":1773306468,"startTime":"0","endTime":"0","summary":"金吾财讯 | 有报道引述消息人士称，金斯瑞生物科技(01548)联营公司传奇生物计划今年在香港上市，集资3亿至4亿美元。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/MjI2MDllNmU0MDE4OTQyNzM4NTczYjJhMDY4OTU0MjU2ODIwNTMx.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MjI2MDllNmU0MDE4OTQyNzM4NTczYjJhMDY4OTU0MjU2ODIwNTMx.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976400","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320223.HKD","BK4588","BK4139","BK1576","HK0000306701.USD","BK4585","01548","BK1583","LEGN","BK4505","HK0000306685.HKD","HK0000320264.USD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618911602","title":"大摩：降金斯瑞生物科技(01548)目标价至16.5港元 维持“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2618911602","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618911602?lang=zh_cn&edition=full","pubTime":"2026-03-11 15:40","pubTimestamp":1773214838,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利发布研报称，金斯瑞生物科技(01548)发盈警后，已将其2026至30年的盈测下调1%至13%，相应目标价由18.3港元下调至16.5港元，维持“增持”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618951830","title":"金斯瑞生物科技(01548)发盈警，预期2025年度亏损约5.06亿美元至5.86亿美元 同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2618951830","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618951830?lang=zh_cn&edition=full","pubTime":"2026-03-10 22:34","pubTimestamp":1773153297,"startTime":"0","endTime":"0","summary":"于本公告日期，公司预计将在报告期的年度业绩中取得减值亏损约3.78亿美元至4.38亿美元。集团预计于报告期内将取得亏损约5.06亿美元至5.86亿美元，而上期则取得利润约29亿美元。报告期内传奇的经调整净亏损由上期的1.89亿美元收窄至报告期的3310万美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"金斯瑞生物科技(01548)发盈警，预期2025年度亏损约5.06亿美元至5.86亿美元 同比盈转亏","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","HK0000306685.HKD","01548","HK0000320264.USD","BK1583","BK1576","HK0000306701.USD","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135386928","title":"金斯瑞生物科技2025财年许可收益最高2.99亿美元，经调整净利润最高2.42亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135386928","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135386928?lang=zh_cn&edition=full","pubTime":"2026-03-10 22:34","pubTimestamp":1773153258,"startTime":"0","endTime":"0","summary":"本期信息\n根据金斯瑞生物科技（股票代码：01548）公告，2025财年（截至2025年12月31日止年度）经调整净利润预计约2.07亿美元至2.42亿美元，相较上期约0.60亿美元增长246.5%至304.3%。公告显示，本期盈利能力的增长主要得益于许可收益的显著提升。公司预计本期许可收益约2.56亿美元至2.99亿美元，上期为约0.024亿美元。\n业务分项\n公告指出，上述许可收益的增长主要来自礼新医药科技有限公司带来的分许可收益。管理层认为，此项收入迅速扩大是推动公司整体盈利能力提升的重要动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genscript.com","stockEarnings":[{"period":"1week","weight":-0.0402},{"period":"1month","weight":0.2382},{"period":"3month","weight":0.0591},{"period":"6month","weight":-0.154},{"period":"1year","weight":0.245},{"period":"ytd","weight":0.0966}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.055},{"period":"3month","weight":-0.0664},{"period":"6month","weight":0.0079},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"金斯瑞生物科技股份有限公司是一家主要从事生产及销售生命科学研究产品及服务的投资控股公司。该公司通过五个分部开展业务。生命科学服务及产品分部提供全面的研究服务及产品。生物制剂开发服务分部以一个综合平台提供全面服务，旨在帮助生物制药及生物技术公司加快治疗性抗体及基因、细胞疗法产品的开发。工业合成生物产品分部通过使用基因工程建构非病源微生物株，提供工业酶开发和生产。细胞疗法分部发现和开发用于治疗液体及固体肿瘤的CAR-T疗法。经营管理分部主要为其他分部提供共享服务。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.000341},{"month":2,"riseRate":0.545455,"avgChangeRate":0.075475},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.060575},{"month":4,"riseRate":0.545455,"avgChangeRate":0.057053},{"month":5,"riseRate":0.5,"avgChangeRate":0.068155},{"month":6,"riseRate":0.6,"avgChangeRate":0.044564},{"month":7,"riseRate":0.6,"avgChangeRate":0.075818},{"month":8,"riseRate":0.4,"avgChangeRate":0.101263},{"month":9,"riseRate":0.4,"avgChangeRate":-0.071937},{"month":10,"riseRate":0.6,"avgChangeRate":0.095918},{"month":11,"riseRate":0.6,"avgChangeRate":0.045101},{"month":12,"riseRate":0.3,"avgChangeRate":0.042047}],"exchange":"SEHK","name":"金斯瑞生物科技","nameEN":"GENSCRIPT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金斯瑞生物科技,01548,金斯瑞生物科技股票,金斯瑞生物科技股票老虎,金斯瑞生物科技股票老虎国际,金斯瑞生物科技行情,金斯瑞生物科技股票行情,金斯瑞生物科技股价,金斯瑞生物科技股市,金斯瑞生物科技股票价格,金斯瑞生物科技股票交易,金斯瑞生物科技股票购买,金斯瑞生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}